Clinical Trials

27 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02453282 2026-05-12

MYSTIC

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT07081633 2026-05-12

TREMENDOUS-2

114 enrolled

Carcinoma, Hepatocellular

NCT03601455 2026-05-11

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

13 enrolled

Urinary Bladder Neoplasms

NCT03482102 2026-05-04

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

37 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT05883644 2026-04-30

SIERRA

111 enrolled

Liver Neoplasms

NCT06045975 2026-04-24

DUMELEP

30 enrolled

Carcinoma, Hepatocellular

NCT03043872 2026-04-22

CASPIAN

987 enrolled 42 charts 1 FDA

Small Cell Lung Carcinoma

NCT03837899 2026-04-21

Durvalumab and Tremelimumab for Pediatric Malignancies

Other hematologic neoplasm

50 enrolled 59 charts

Neoplasms, Hematologic Neoplasms

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Phase 1 Active not recruiting

Urothelial Cancer

NCT04605731 2026-04-20

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

25 enrolled

Carcinoma, Hepatocellular

NCT04960709 2026-04-14

VOLGA

712 enrolled

Urinary Bladder Neoplasms

NCT02888743 2026-04-13

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04034927 2026-04-13

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

61 enrolled 15 charts

Gynecologic

Fallopian Tube Neoplasms

NCT05301842 2026-04-07

EMERALD-3

760 enrolled

Phase 1 Active not recruiting

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

25 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06008093 2026-03-30

TRITON

100 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02537418 2026-03-27

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

153 enrolled

Solid Malignancies

NCT03410615 2026-03-24

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

129 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03298451 2026-03-20

HIMALAYA

1,324 enrolled 31 charts 1 FDA

Carcinoma, Hepatocellular

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

NCT01843374 2026-03-05

Tremelimumab

Other solid neoplasmThoracic

571 enrolled 19 charts

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

NCT02812420 2026-03-05

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Phase EARLY_PHASE1 Active not recruiting

54 enrolled

Hydronephrosis, Ureteral Neoplasms, Urethral Neoplasms

NCT03057106 2026-03-03

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

301 enrolled 15 charts

Lung Cancer Metastatic

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

433 enrolled 26 charts

Carcinoma, Hepatocellular

NCT03965468 2026-02-09

CHESS

96 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04395079 2026-02-09

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

9 enrolled

Metastatic Malignant Female Reproductive System Neoplasm

NCT03682068 2026-02-03

NILE

1,246 enrolled

Urinary Bladder Neoplasms

NCT03158064 2026-01-28

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

30 enrolled

Nonseminomatous germ cell tumor, Dysgerminoma, Neoplasms, Germ Cell and Embryonal, Germinoma, Seminoma

NCT04238637 2025-12-05

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

50 enrolled

Cholangiocarcinoma

NCT03703297 2025-11-21

ADRIATIC

730 enrolled 19 charts 1 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT02962063 2025-09-05

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

64 enrolled

Adenocarcinoma Of Esophagus

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

200 enrolled

Prostatic Neoplasms

NCT04817826 2025-06-10

INFINITY

31 enrolled

Stomach Neoplasms, Microsatellite Instability

NCT02571725 2025-05-23

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

50 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05000710 2024-12-05

CORAL-Lung

29 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03959293 2024-07-08

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

107 enrolled

Stomach Neoplasms

NCT03784066 2024-07-03

DUTRELASCO

21 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03283605 2024-06-28

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

45 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04169841 2024-02-13

GUIDE2REPAIR